Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.

Trial Profile

A Multiple-dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and QTc Effect of MK-8189 in Participants With Schizophrenia and Healthy Participants.

Suspended
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs MK 8189 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Acronyms MDCS
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Dec 2018 Planned End Date changed from 31 Dec 2018 to 9 Oct 2019.
    • 11 Dec 2018 Planned primary completion date changed from 31 Dec 2018 to 9 Oct 2019.
    • 11 Dec 2018 Status changed from recruiting to suspended pending evaluation of emerging preclinical findings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top